No retraction, correction or concern found when last checked on Oct 17, 2026.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Sandhya Bangaru, Gabriel Ozorowski, Hannah L. Turner and 15 more (opens in a new tab)
Science · 2020 · CC BY
doi:10.1126/science.abe1502 (opens in a new tab)
Abstract
Structure of a vaccine candidate Much effort is being targeted at developing vaccines that will provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A trimeric spike protein that decorates the virus is a primary target of the host immune system and the focus of vaccine development. Bangaru et al. present the structure of a leading vaccine candidate: a full-length spike protein with some modifications aimed at enhancing stability that is formulated in polysorbate 80 detergent. The study confirms that the full-length immunogen is in a stable prefusion conformation and provides a basis for understanding immune responses to the vaccine. Science , this issue p. 1089
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
Severe acute respiratory syndrome coronavirus (SARS-CoV) caused a global outbreak from 2002 to 2003. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the same lineage of the β-CoV genus as SARS-CoV, recently emerged in China and spread rapidly, infecting more than 28 million people worldwide by September 2020. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, was declared a pandemic by the World Health Organization (WHO). In response, several SARS-CoV-2 vaccine candidates are being developed and tested at various stages of clinical trials. The SARS-CoV-2 spike (S) trimeric glycoprotein is a focus of vaccine development because it is the primary target of host immune defenses.
Like other type 1 fusion proteins, the SARS-CoV-2 S prefusion trimer is metastable and undergoes structural rearrangement from a prefusion to a postfusion conformation upon S-protein receptor binding and cleavage. The structure of the stabilized SARS-CoV-2 spike ectodomain has been solved in its prefusion conformation and resembles the SARS-CoV spike. Here, we describe the structure of a leading SARS-CoV-2 S vaccine candidate (NVAX-CoV2373) based on a full-length (FL) S, residues 1 to 1273, which includes the transmembrane (TM) and the cytoplasmic tail (CT) (Fig. 1A). The final construct, SARS-CoV-2-3Q-2P, was also modified at the S1/S2 polybasic cleavage site from RRAR to QQAQ to render it protease resistant, along with two proline substitutions at residues K986 and V987 in the S2 fusion machinery core for enhanced stability (Fig. 1A). The FL spikes, expressed and purified from insect cells, were formulated in 0.01% (v/v) polysorbate 80 (PS 80) detergent. To characterize the structural integrity of the 3Q-2P-FL immunogen, we performed negative-stain electron microscopy of the FL spike constituted in PS 80 in the presence of Matrix-M adjuvant, recapitulating the vaccine formulation being tested in humans. Imaging revealed trimeric spike proteins present as free trimers or as multitrimer rosettes, containing as many as 14 trimers with their TM domains enclosed in micellar cores of PS 80 detergent (Fig. 1B). Tight clustering of the spikes in the NVAX-CoV2373 nanoparticle formulation may lead to stronger immune responses over soluble trimers alone, similar to other viral glycoprotein immunogens (hemagglutinin and respiratory syncytial virus F).
We next performed single-particle cryo–electron microscopy (cryo-EM) on the spike formulated in PS 80 detergent (Fig. 2A). Initial two-dimensional (2D) classification revealed the presence of two distinct classes: free spike trimers and dimers of trimers (Fig. 2A). The threefold symmetric (C3) reconstruction of the free spike trimer resulted in a 3.6 Å–resolution map, whereas the asymmetric reconstruction (C1) was refined to 3.8-Å resolution (Fig. 2B and fig. S1, A and B). In previous structures, receptor binding domains (RBDs) exist in either a closed (RBD-down) or an open (RBD-up) conformation that can engage in ACE2 binding. By contrast, we observed that all three RBDs on the 3Q-2P-FL spike trimer were in the closed conformation in our reconstructions (Fig. 2B and fig. S1C). Despite the RBD-down conformation, binding analysis of the 3Q-2P-FL immunogen to ACE2 by both biolayer interferometry and enzyme-linked immunosorbent assay clearly shows binding to ACE2, indicating that the RBD is dynamic and the receptor binding site accessible. Another study on the prefusion structure of an FL spike protein reported similar findings with RBDs clamped down as a consequence of potential clashes between S2 residues 828 to 853 and subdomain 1 (SD1) when RBD is in open conformation. Recent reports by Henderson et al. have revealed that introducing mutations and removing N-linked glycosylation at certain positions can alter the propensity toward “up” and “down” states of the RBD.
Overall, our cryo-EM map was well resolved in both S1 and S2 subunits (fig. S1D), enabling us to model the full S1 N-terminal domain (NTD) and C-terminal domain (CTD) that were less resolved in previous structures. Our final atomic model contains residues 14 to 1146 with breaks only in the flexible loop (619 to 631) and the cleavage site (678 to 688) (Fig. 2C). Superimposition of the coordinate models of 3Q-2P-FL spike with published spike structures [Protein Data Bank (PDB) IDs: 6VXX and 6VSB] revealed substantial domain rearrangements in the S1 subunit of 3Q-2P-FL spike (Fig. 2D). The S1 NTD rotated ~14° relative to published models, whereas the CTD and subdomains showed minor local rearrangements (Fig. 2D). Another recent study also observed differences in NTD conformations at lower pH, although our cryo-EM studies were carried out at neutral pH. In our 3Q-2P-FL structure, we observed a shift in residues flanking the 615 to 635 loop, resulting in a salt bridge between residue D614 on one protomer and K854 on a neighboring protomer (Fig. 3A). This observation is particularly notable given the increased prevalence of D614→G (D614G) mutation in the emerging SARS-CoV-2 strains and its potential role in viral transmission and pathogenesis. The 615 to 635 loop that is generally disordered in spike trimer structures, including ours, was recently modeled as a helix (PDB ID: 6X6P) (Fig. 3B), although the cryo-EM density (EMD-22078) does not support this assignment (fig. S1E).
We observed two additional densities in the S1 subunit that did not correspond to peptide or glycans within the spike (fig. S2A). The first density was buried within a hydrophobic pocket of the CTD (Fig. 3C). We have previously showed palmitoleic acid occupying a similar pocket in the structure of porcine epidemic diarrhea virus. This density in SARS-CoV-2 S corresponded to linoleic acid, a polyunsaturated fatty acid; the presence of this ligand was confirmed by mass spectrometry of 3Q-2P-FL spike (fig. S2, B and C). The main chain carboxyl group of linoleic acid interacts with the R408 and Q409 residues of the RBD from the adjacent protomer, potentially stabilizing the observed RBD-down state (Fig. 3C) and consistent with a recent report. The second unassigned density, present in the NTD, was larger and more surface exposed than the first (Fig. 3D and fig. S2D). The aliphatic tail of PS 80 fit well into this hydrophobic pocket, whereas the carbonyl and hydroxyl groups were in proximity to residues R190 and H207 with potential for multiple hydrogen bonds between them (Fig. 3D and fig. S2D). The location of the PS 80 ligand provides a possible explanation for the S1 shift seen in our FL trimer density. PS 80 is specific to the formulation of the Novavax 3Q-2P-FL immunogen, but other ligands may also bind this pocket and provide a potential target for drug design against SARS-CoV-2.
Classification of multimeric spike trimer particles yielded two separate classes: a dimer-of-trimers class that reconstructed to a final resolution of 4.5 Å with twofold symmetry and a trimer-of-trimers class that was resolved to 8.0-Å resolution (Fig. 4, A and B, and fig. S3A). In both reconstructions, the interaction between each pair of trimers involved the SD2 of one protomer from each trimer engaging with the NTD of the adjacent trimer (Fig. 4C), with trimer axes tilted 44.5° relative to each other. The dimer-of-trimer interaction was mainly coordinated by the 615 to 635 loop, which, in contrast to the free-trimer structure, was now fully resolved (Fig. 4D). The loop reaches into and induces subtle changes to a pocket on the adjacent NTD compared with the free-trimer model (Fig. 4D). Residues Y145 and H146 in the binding pocket appear to switch positions in the loop-bound state, resulting in a salt-bridge interaction between H146 and D627 and potential stacking between W152 and H146 (Fig. 4E). We also observed minor displacement of residues 68 to 75 and 248 to 250 surrounding the pocket. In the dimer-of-trimers, we also observed N282 glycans at the dimer interface (fig. S3B). As a control, we also performed cryo-EM studies of the SARS-CoV-2-3Q-FL (without 2P). Notably, the structures of the trimers were identical, and we also observed dimers of trimers (fig. S3, C to E)
Sequence alignment of residues in the 615 to 635 loop and corresponding NTD binding pocket across representative CoV strains belonging to lineage B of betacoronaviruses revealed residues 621-PVAIHADQ-628 are well conserved, but there are notable differences in the binding pocket residues (fig. S4A). Substantial gaps in the interacting NTD loops along with the absence of H146 at the corresponding site on SARS-CoV make it unlikely that SARS-CoV participates in similar intertrimeric interactions. Although the residues in the NTD pocket were almost identical between SARS-CoV-2 and its closely related bat strain Bat-SL-RatG13, we observed some residue differences and one to three amino acid deletions in the loops comprising the NTD binding pocket of representative strains Bat-SL-CoVZC45, BetaCoV/pangolin/Guangdong/1/2019, and BetaCoV/pangolin/Guangxi/P4L/2007 (fig. S4A).
Some human CoVs, including OC43, exclusively use NTD–sialic acid (SA) interactions as their receptor engagement, whereas others such as Middle East respiratory syndrome (MERS) CoV that use the CTD-RBD for primary receptor binding have also been reported to bind SA receptors through their NTD to aid initial attachment to the host cells. Structural comparisons of the SARS-CoV-2 NTD dimerization pocket with that of the SA binding site on MERS spike revealed that they did not coincide with each other (PDB ID: 6Q04) (fig. S4B). Computational and structural studies have proposed residues on SARS-CoV-2 spike that may be involved in SA binding. Structural comparison of this putative glycan binding site to the dimerization site revealed them situated adjacent to one another with residues in loop 70 contributing to both the binding pockets (fig. S4C).
We next performed cell surface expression and pseudovirus replication assays with SARS-CoV-2 wild-type (WT) spike and spikes containing mutations in the 615 to 635 loop and NTD pocket. Each residue in the loop 621-PVAIHADQ-628 and residue H146 in the binding pocket were individually mutated to either alanine or glycine. Additionally, we made a spike construct with all eight residues 621-PVAIHADQ-628 replaced with a glycine-serine (GS) linker to completely abrogate binding. Compared with the WT, the mutants generally exhibited lower levels of infectivity (Fig. 4F). Cell surface expression of these mutants in 293T cells revealed that these mutations also disrupted surface expression of the spike protein, with linear correlation between surface expression and pseudovirus replication (Fig. 4G).
Glycans on viral glycoproteins play a wide role in protein folding, stability, and immune recognition and also in facilitating immune evasion. We therefore conducted site-specific glycosylation analysis of the SARS-CoV-2 prefusion spike protein produced in Sf9 insect cells as previously described to assess the extent of glycosylation and the degree of glycan processing from high-mannose or hybrid type to complex type. The analysis detected glycosylation at all 22 N-linked glycan sequons present on SARS-CoV-2 spike (Fig. 4H). Overall, there was high glycan occupancy of >98%, with only two sites (603 and 657) >5% unoccupied. We did not see clear glycan density at either 603 or 657 in the cryo-EM reconstruction of the 3Q-2P-FL spike. Most sites showed extensive glycan processing to complex or paucimannose-type glycans, with only four sites exhibiting ≥40% oligomannose. The glycan analysis also confirmed the presence of glycans at sites 1158, 1173, and 1194 present in the membrane-proximal region of the spike not resolved by cryo-EM. By comparison with site-specific glycan processing of the spike protein produced in mammalian human embryonic kidney (HEK) 293F cells, both mammalian cells and insect cells exhibit extensive processing at most sites. In general, however processing of glycans on the 2019 CoV prefusion spike protein from insect cells was somewhat greater, particularly at sites 709 and 717, which were predominately oligomannose in spike from HEK293 cells but exclusively complex or paucimannose in spike from Sf9 cells.
Our structural work is consistent with the burgeoning body of spike structures, albeit with notable differences in the rearrangement of S1 domains and formation of intertrimer interactions. Both these findings were seen in the FL spike immunogens assembled into compact and dense nanoparticles. Cryo–electron tomographic reconstructions of intact SARS-CoV-2 virions showed a relatively dispersed distribution of spike protein trimers on the viral surface and no evidence of higher-order aggregates. However, another study showed that the D614G mutation present in close proximity to the dimerization loop results in a several-fold increase of spike numbers on the viral surface, resulting in higher spike protein density and a more infectious virion. The greater density may be aided by the ability to form such higher-order multimers. Alternatively, the loop that mediates interspike interactions may play a role in viral viability, consistent with our loop mutant data.
Analysis of safety and immunogenicity of the Novavax SARS-CoV-2-3Q-2P-FL immunogen in mice and baboons revealed strong B and T cell responses to the vaccine with no evidence of vaccine-associated enhanced respiratory disease. Phase 1 and 2 clinical trial results showed that the vaccine induced immune responses exceeding levels seen in COVID-19 patients. Overall, we found that NVAX-CoV2372 is stable, homogeneous, and locked in the antigenically preferred prefusion conformation. With structural, biophysical, and antigenic characterization now complete, ongoing evaluation in humans will provide the true proof-of-principle for this vaccine concept.
References 52
- 1.
J. D. Cherry, P. Krogstad, SARS: The first pandemic of the 21st century. Pediatr. Res. 56, 1–5 (2004 ).
Not in our library10.1203/01.pdr.0000129184.87042.fc (opens in a new tab)
- 2.
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, China Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020 ).
Not in our library10.1056/nejmoa2001017 (opens in a new tab)
- 3.
F. Amanat, F. Krammer, SARS-CoV-2 vaccines: Status report. Immunity 52, 583–589 (2020 ).
Not in our library10.1016/j.immuni.2020.03.007 (opens in a new tab)
- 4.
N. Lurie, M. Saville, R. Hatchett, J. Halton, Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969–1973 (2020 ).
Not in our library10.1056/nejmp2005630 (opens in a new tab)
- 5.
- 6.
- 7.
A. C. Walls, M. A. Tortorici, J. Snijder, X. Xiong, B.-J. Bosch, F. A. Rey, D. Veesler, Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 114, 11157–11162 (2017 ).
Not in our library10.1073/pnas.1708727114 (opens in a new tab)
- 8.
B. J. Bosch, R. van der Zee, C. A. de Haan, P. J. Rottier, The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J. Virol. 77, 8801–8811 (2003 ).
Not in our library10.1128/jvi.77.16.8801-8811.2003 (opens in a new tab)
- 9.
A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veesler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020 ).
Not in our library10.1016/j.cell.2020.02.058 (opens in a new tab)
- 10.
D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020 ).
Not in our library10.1126/science.abb2507 (opens in a new tab)
- 11.
N. G. Herrera, N. C. Morano, A. Celikgil, G. I. Georgiev, R. J. Malonis, J. H. Lee, K. Tong, O. Vergnolle, A. B. Massimi, L. Y. Yen, A. J. Noble, M. Kopylov, J. B. Bonanno, S. C. Garrett-Thomson, D. B. Hayes, R. H. Bortz, A. S. Wirchnianski, C. Florez, E. Laudermilch, D. Haslwanter, J. M. Fels, M. E. Dieterle, R. K. Jangra, J. Barnhill, A. Mengotto, D. Kimmel, J. P. Daily, L. A. Pirofski, K. Chandran, M. Brenowitz, S. J. Garforth, E. T. Eng, J. R. Lai, S. C. Almo, Characterization of the SARS-CoV-2 S protein: Biophysical, biochemical, structural, and antigenic analysis. bioRxiv 2020.06.14.150607 [Preprint]. 17 June 2020;.
Not in our library10.1101/2020.06.14.150607 (opens in a new tab)
- 12.
- 13.
V. Shinde, L. Fries, Y. Wu, S. Agrawal, I. Cho, D. N. Thomas, M. Spindler, E. Lindner, T. Hahn, J. Plested, D. Flyer, M. J. Massare, B. Zhou, A. Fix, G. Smith, G. M. Glenn, Improved titers against influenza drift variants with a nanoparticle vaccine. N. Engl. J. Med. 378, 2346–2348 (2018 ).
Not in our library10.1056/nejmc1803554 (opens in a new tab)
- 14.
J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020 ).
Not in our library10.1038/s41586-020-2179-y (opens in a new tab)
- 15.
- 16.
- 17.
R. Henderson, R. J. Edwards, K. Mansouri, K. Janowska, V. Stalls, M. Kopp, B. F. Haynes, P. Acharya, Glycans on the SARS-CoV-2 spike control the receptor binding domain conformation. bioRxiv 2020.06.26.173765 [Preprint]. 26 June 2020;.
Not in our library10.1101/2020.06.26.173765 (opens in a new tab)
- 18.
R. Henderson, R. J. Edwards, K. Mansouri, K. Janowska, V. Stalls, S. M. C. Gobeil, M. Kopp, D. Li, R. Parks, A. L. Hsu, M. J. Borgnia, B. F. Haynes, P. Acharya, Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol. 27, 925–933 (2020 ).
Not in our library10.1038/s41594-020-0479-4 (opens in a new tab)
- 19.
T. Zhou, Y. Tsybovsky, A. S. Olia, J. Gorman, M. A. Rapp, G. Cerutti, P. S. Katsamba, A. Nazzari, A. Schon, P. D. Wang, J. Bimela, W. Shi, I. T. Teng, B. Zhang, J. C. Boyington, G. Y. Chuang, J. M. Sampson, M. Sastry, T. Stephens, J. Stuckey, S. Wang, R. A. Friesner, D. D. Ho, J. R. Mascola, L. Shapiro, P. D. Kwong, A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike. bioRxiv 2020.07.04.187989 [Preprint]. 4 July 2020;.
Not in our library10.1101/2020.07.04.187989 (opens in a new tab)
- 20.
- 21.
R. N. Kirchdoerfer, M. Bhandari, O. Martini, L. M. Sewall, S. Bangaru, K.-J. Yoon, A. B. Ward, Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. bioRxiv 2020.02.18.955195 [Preprint]. 19 February 2020;.
Not in our library10.1101/2020.02.18.955195 (opens in a new tab)
- 22.
- 23.
R. J. G. Hulswit, Y. Lang, M. J. G. Bakkers, W. Li, Z. Li, A. Schouten, B. Ophorst, F. J. M. van Kuppeveld, G.-J. Boons, B.-J. Bosch, E. G. Huizinga, R. J. de Groot, Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Natl. Acad. Sci. U.S.A. 116, 2681–2690 (2019 ).
Not in our library10.1073/pnas.1809667116 (opens in a new tab)
- 24.
W. Li, R. J. G. Hulswit, I. Widjaja, V. S. Raj, R. McBride, W. Peng, W. Widagdo, M. A. Tortorici, B. van Dieren, Y. Lang, J. W. M. van Lent, J. C. Paulson, C. A. M. de Haan, R. J. de Groot, F. J. M. van Kuppeveld, B. L. Haagmans, B.-J. Bosch, Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 114, E8508–E8517 (2017 ).
Not in our library10.1073/pnas.1712592114 (opens in a new tab)
- 25.
Y. J. Park, A. C. Walls, Z. Wang, M. M. Sauer, W. Li, M. A. Tortorici, B.-J. Bosch, F. DiMaio, D. Veesler, Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol. 26, 1151–1157 (2019 ).
Not in our library10.1038/s41594-019-0334-7 (opens in a new tab)
- 26.
E. Milanetti, M. Miotto, L. Di Rienzo, M. Monti, G. Gosti, G. Ruocco, In-silico evidence for two receptors based strategy of SARS-CoV-2. bioRxiv 2020.03.24.006197 [Preprint]. 6 April 2020;.
Not in our library10.1101/2020.03.24.006197 (opens in a new tab)
- 27.
M. Awasthi, S. Gulati, D. P. Sarkar,, S. Tiwari, S. Kateriya, P. Ranjan, S. K. Verma, The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein Structurally Resembles MERS-CoV. Viruses 12, 909 (2020 ).
Not in our library10.3390/v12090909 (opens in a new tab)
- 28.
- 29.
- 30.
Z. Ke, J. Oton, K. Qu, M. Cortese, V. Zila, L. McKeane, T. Nakane, J. Zivanov, C. J. Neufeldt, B. Cerikan, J. M. Lu, J. Peukes, X. Xiong, H.-G. Kräusslich, S. H. W. Scheres, R. Bartenschlager, J. A. G. Briggs, Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 10.1038/s41586-020-2665-2 (2020 ).
Not in our library10.1038/s41586-020-2665-2 (opens in a new tab)
- 31.
C. Keech, G. Albert, I. Cho, A. Robertson, P. Reed, S. Neal, J. S. Plested, M. Zhu, S. Cloney-Clark, H. Zhou, G. Smith, N. Patel, M. B. Frieman, R. E. Haupt, J. Logue, M. McGrath, S. Weston, P. A. Piedra, C. Desai, K. Callahan, M. Lewis, P. Price-Abbott, N. Formica, V. Shinde, L. Fries, J. D. Lickliter, P. Griffin, B. Wilkinson, G. M. Glenn, Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 10.1056/NEJMoa2026920 (2020 ).
Not in our library10.1056/nejmoa2026920 (opens in a new tab)
- 32.
C. S. Potter, H. Chu, B. Frey, C. Green, N. Kisseberth, T. J. Madden, K. L. Miller, K. Nahrstedt, J. Pulokas, A. Reilein, D. Tcheng, D. Weber, B. Carragher, Leginon: A system for fully automated acquisition of 1000 electron micrographs a day. Ultramicroscopy 77, 153–161 (1999 ).
Not in our library10.1016/s0304-3991(99)00043-1 (opens in a new tab)
- 33.
G. C. Lander, S. M. Stagg, N. R. Voss, A. Cheng, D. Fellmann, J. Pulokas, C. Yoshioka, C. Irving, A. Mulder, P.-W. Lau, D. Lyumkis, C. S. Potter, B. Carragher, Appion: An integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95–102 (2009 ).
Not in our library10.1016/j.jsb.2009.01.002 (opens in a new tab)
- 34.
N. R. Voss, C. K. Yoshioka, M. Radermacher, C. S. Potter, B. Carragher, DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205–213 (2009 ).
Not in our library10.1016/j.jsb.2009.01.004 (opens in a new tab)
- 35.
T. Ogura, K. Iwasaki, C. Sato, Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J. Struct. Biol. 143, 185–200 (2003 ).
Not in our library10.1016/j.jsb.2003.08.005 (opens in a new tab)
- 36.
C. Suloway, J. Pulokas, D. Fellmann, A. Cheng, F. Guerra, J. Quispe, S. Stagg, C. S. Potter, B. Carragher, Automated molecular microscopy: The new Leginon system. J. Struct. Biol. 151, 41–60 (2005 ).
Not in our library10.1016/j.jsb.2005.03.010 (opens in a new tab)
- 37.
S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017 ).
Not in our library10.1038/nmeth.4193 (opens in a new tab)
- 38.
A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017 ).
Not in our library10.1038/nmeth.4169 (opens in a new tab)
- 39.
- 40.
- 41.
- 42.
- 43.
B. A. Barad, N. Echols, R. Y.-R. Wang, Y. Cheng, F. DiMaio, P. D. Adams, J. S. Fraser, EMRinger: Side chain-directed model and map validation for 3D cryo-electron microscopy. Nat. Methods 12, 943–946 (2015 ).
Not in our library10.1038/nmeth.3541 (opens in a new tab)
- 44.
C. J. Williams, J. J. Headd, N. W. Moriarty, M. G. Prisant, L. L. Videau, L. N. Deis, V. Verma, D. A. Keedy, B. J. Hintze, V. B. Chen, S. Jain, S. M. Lewis, W. B. Arendall III, J. Snoeyink, P. D. Adams, S. C. Lovell, J. S. Richardson, D. C. Richardson, MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018 ).
Not in our library10.1002/pro.3330 (opens in a new tab)
- 45.
N. W. Moriarty, R. W. Grosse-Kunstleve, P. D. Adams, electronic Ligand Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint generation. Acta Crystallogr. D 65, 1074–1080 (2009 ).
Not in our library10.1107/s0907444909029436 (opens in a new tab)
- 46.
T. D. Goddard, C. C. Huang, E. C. Meng, E. F. Pettersen, G. S. Couch, J. H. Morris, T. E. Ferrin, UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018 ).
Not in our library10.1002/pro.3235 (opens in a new tab)
- 47.
E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004 ).
Not in our library10.1002/jcc.20084 (opens in a new tab)
- 48.
- 49.
- 50.
L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Protocol G Principal Investigators, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009 ).
Not in our library10.1126/science.1178746 (opens in a new tab)
- 51.
V. Tretter, F. Altmann, L. März, Peptide-N4-(N-acetyl-β-glucosaminyl)asparagine amidase F cannot release glycans with fucose attached α1 → 3 to the asparagine-linked N-acetylglucosamine residue. Eur. J. Biochem. 199, 647–652 (1991 ).
Not in our library10.1111/j.1432-1033.1991.tb16166.x (opens in a new tab)
- 52.
E. Staudacher, V. Kubelka, L. März, Distinct N-glycan fucosylation potentials of three lepidopteran cell lines. Eur. J. Biochem. 207, 987–993 (1992 ).
Not in our library10.1111/j.1432-1033.1992.tb17134.x (opens in a new tab)
Cited by papers we hold 11
- Learning from prepandemic data to forecast viral escape · 2023No notice
- A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022No notice
- mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022No notice
- Advances in COVID-19 mRNA vaccine development · 2022No notice
- SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants · 2021No notice
- Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class · 2021Not checked
- Structural impact on SARS-CoV-2 spike protein by D614G substitution · 2021No notice
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant · 2021No notice
- Protein-based antigen presentation platforms for nanoparticle vaccines · 2021No notice
- Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action · 2021No notice
- SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity · 2020No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.